EP0737314A1 - Verwendungen für gal 4-rezeptor-konstrukte - Google Patents

Verwendungen für gal 4-rezeptor-konstrukte

Info

Publication number
EP0737314A1
EP0737314A1 EP95905946A EP95905946A EP0737314A1 EP 0737314 A1 EP0737314 A1 EP 0737314A1 EP 95905946 A EP95905946 A EP 95905946A EP 95905946 A EP95905946 A EP 95905946A EP 0737314 A1 EP0737314 A1 EP 0737314A1
Authority
EP
European Patent Office
Prior art keywords
receptor
gal4
ligand
binding domain
steroid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP95905946A
Other languages
English (en)
French (fr)
Other versions
EP0737314A4 (de
Inventor
Ronald M. Evans
Kazuhiko Umesono
Bruce Blumberg
Pundi N. Rangarajan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Salk Institute for Biological Studies
Original Assignee
Salk Institute for Biological Studies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salk Institute for Biological Studies filed Critical Salk Institute for Biological Studies
Priority to EP96111192A priority Critical patent/EP0743520A3/de
Publication of EP0737314A1 publication Critical patent/EP0737314A1/de
Publication of EP0737314A4 publication Critical patent/EP0737314A4/de
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C07K14/395—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EP95905946A 1993-12-30 1994-12-29 Verwendungen für gal 4-rezeptor-konstrukte Ceased EP0737314A4 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP96111192A EP0743520A3 (de) 1993-12-30 1994-12-29 Neue Verwendungen von Gal4-Rezeptor-Konstruktionen

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17774093A 1993-12-30 1993-12-30
US177740 1993-12-30
PCT/US1994/014426 WO1995018380A1 (en) 1993-12-30 1994-12-29 Novel uses for gal4-receptor constructs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP96111192A Division EP0743520A3 (de) 1993-12-30 1994-12-29 Neue Verwendungen von Gal4-Rezeptor-Konstruktionen

Publications (2)

Publication Number Publication Date
EP0737314A1 true EP0737314A1 (de) 1996-10-16
EP0737314A4 EP0737314A4 (de) 1999-11-03

Family

ID=22649809

Family Applications (2)

Application Number Title Priority Date Filing Date
EP95905946A Ceased EP0737314A4 (de) 1993-12-30 1994-12-29 Verwendungen für gal 4-rezeptor-konstrukte
EP96111192A Withdrawn EP0743520A3 (de) 1993-12-30 1994-12-29 Neue Verwendungen von Gal4-Rezeptor-Konstruktionen

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP96111192A Withdrawn EP0743520A3 (de) 1993-12-30 1994-12-29 Neue Verwendungen von Gal4-Rezeptor-Konstruktionen

Country Status (5)

Country Link
EP (2) EP0737314A4 (de)
JP (2) JPH09504111A (de)
AU (2) AU1436695A (de)
CA (2) CA2180271A1 (de)
WO (1) WO1995018380A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0737314A4 (de) * 1993-12-30 1999-11-03 Salk Inst For Biological Studi Verwendungen für gal 4-rezeptor-konstrukte
US6770446B1 (en) 1994-06-14 2004-08-03 Wyeth Cell systems having specific interaction of peptide binding pairs
US5989808A (en) 1994-06-14 1999-11-23 American Cyanamid Company Identification of compounds affecting specific interaction of peptide binding pairs
CA2204616C (en) * 1995-09-18 2002-12-17 Ranjan Mukherjee Ppar gamma antagonists for treating obesity
US6555339B1 (en) * 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
EP0977892A1 (de) 1997-04-24 2000-02-09 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methoden und zusammensetzungen zur regulation der expresssion von matrix-metalloproteinase genen
PT1016714E (pt) 1997-06-27 2003-09-30 Ono Pharmaceutical Co Novo adn plasmidico que compreende adn do gene reporter e sua utilizacao
WO1999005292A1 (en) * 1997-07-22 1999-02-04 Chugai Seiyaku Kabushiki Kaisha Method for gene screening with the use of nuclear receptors
WO1999063980A1 (en) 1998-06-12 1999-12-16 Ligand Pharmaceuticals Inc. Treatment of anti-estrogen resistant breast cancer using rxr modulators
AU3725600A (en) * 1999-03-02 2000-09-21 Maxygen, Inc. Surrogate orphan ligands for orphan receptors
EP1743655B1 (de) 2000-01-21 2014-06-25 Novartis AG Zusammensetzungen bestehend aus dipeptidylpeptidase-iv inhibitoren und antidiabetica
WO2002097099A1 (en) * 2001-05-29 2002-12-05 Valentis, Inc. Regulated expression of ghrh
ES2367539T3 (es) 2001-12-21 2011-11-04 X-Ceptor Therapeutics, Inc. Moduladores heterocíclicos de receptores nucleares.
EP1388352A1 (de) 2002-08-08 2004-02-11 Laboratoires Fournier S.A. Verwendung eines ppar-alpha-Agonisten zur Behandlung von Patienten, die an mit ppar-gamma-Agonisten-Behandlung assozierter Fettleibigkeit leiden
EP1544307A1 (de) * 2003-12-18 2005-06-22 AXXAM S.r.l. Chimärer LAC9 Rezeptor und dessen Verwendungen
BRPI0612287A8 (pt) 2005-06-27 2019-01-22 Exelixis Inc composição para uso farmacêutico no tratamento de doenças através da medicina nuclear e métodos de uso e para modulação de atividade de receptor nuclear
PT1931350E (pt) 2005-09-14 2014-02-12 Takeda Pharmaceutical Administração de inibidores de dipeptidil peptidase
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
PL2531501T3 (pl) 2010-02-03 2014-05-30 Takeda Pharmaceuticals Co Inhibitory kinazy 1 regulującej sygnał apoptotyczny
WO2013037482A1 (en) 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Farnesoid x receptor agonists for cancer treatment and prevention
US9074186B2 (en) 2012-08-15 2015-07-07 Boston Medical Center Corporation Production of red blood cells and platelets from stem cells

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6492137B1 (en) * 1989-11-16 2002-12-10 The Salk Institute For Biological Studies Response element compositions and assays employing same
CA2115452A1 (en) * 1991-09-17 1993-04-01 Ronald M. Evans Receptor of the thyroid/steroid hormone receptor superfamily
EP0745121B1 (de) * 1992-05-14 2007-06-20 Baylor College Of Medicine Mutierte steroidhormonrezeptoren, methoden für ihre benutzung und molekularer schalter für gentherapie
EP0737314A4 (de) * 1993-12-30 1999-11-03 Salk Inst For Biological Studi Verwendungen für gal 4-rezeptor-konstrukte

Also Published As

Publication number Publication date
CA2182908A1 (en) 1995-07-01
WO1995018380A1 (en) 1995-07-06
EP0743520A2 (de) 1996-11-20
EP0743520A3 (de) 1999-11-10
AU700646B2 (en) 1999-01-14
CA2180271A1 (en) 1995-07-06
AU1436695A (en) 1995-07-17
AU5837496A (en) 1996-10-03
JPH09504111A (ja) 1997-04-22
JPH09275988A (ja) 1997-10-28
EP0737314A4 (de) 1999-11-03

Similar Documents

Publication Publication Date Title
AU700646B2 (en) Novel uses for GAL4-receptor constructs
Willy et al. LXR, a nuclear receptor that defines a distinct retinoid response pathway.
AU655912B2 (en) Hormone response element compositions and assay
US5310662A (en) Receptors: their identification, characterization, preparation and use
US5091518A (en) Beta retinoic acid response elements compositions and assays
EP0798378B1 (de) Östrogen-Rezeptor
US5262300A (en) Receptors: their identification, characterization, preparation and use
AU7263198A (en) Compounds useful for the modulation of processes mediated by nuclear hormone receptors, methods for the identification and use of such compounds
CA2218955A1 (en) Selective modulators of peroxisome proliferator activated receptor-gamma, and methods for the use thereof
US5707800A (en) Retinoic acid response elements and assays employing same
US6635429B1 (en) Heterodimeric nuclear receptors proteins, genes encoding same, and usage thereof
CA2194169A1 (en) Mammalian peroxisome proliferator-activated receptors and uses thereof
AU668683B2 (en) Response element compositions and assays employing same
US7098310B1 (en) Heterodimers of retinoid X receptors (RXRS) and other steroid hormone receptors
Repa The biochemical characterization of recombinant retinoid receptors
JP2004519227A (ja) モノマー転写活性化活性を有するＮｕｒｒ１転写因子Ｉ−ボックス変異体
HK1001978B (en) Estrogen receptor

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19960508

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

XX Miscellaneous (additional remarks)

Free format text: TEILANMELDUNG 96111192.9 EINGEREICHT AM 11/07/96.

A4 Supplementary search report drawn up and despatched

Effective date: 19990920

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20000308

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20040113